New findings reveal that the way Aduhelm is packaged leads to wasted medication — and as much as $605 million per year of Medicare…
Reporter Phil Gutis reflects on the seemingly widespread disbelief that anyone diagnosed with a cognitive disease can be a productive, contributing member of society…
The Food and Drug Administration issued an update to Aduhelm’s label, now requiring a total of four MRIs during the first year of treatment…
Biogen has withdrawn the application anti-amyloid Alzheimer’s drug Aduhelm from Europe’s regulatory agency. Biogen has abandoned its application for the approval of anti-amyloid Alzheimer’s…
The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
On the last day of the public comment period for CMS’s Aduhelm coverage proposal, former pediatrician Alan Schooley, now living with early-onset Alzheimer’s, shares…
The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects…